.Attribute Medication, Posted online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research study, after a mean follow-up of 11 months, individuals along with metastatic gastrointestinal cysts who received biomarker-matched treatments based upon spreading cyst DNA profiling showed a greater medical advantage than those acquiring unparalleled therapy.